Gamma Delta T-Cell Therapy (H Lee Moffitt Cancer Center & Research Institute)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameGamma Delta T-Cell Therapy (H Lee Moffitt Cancer Center & Research Institute)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesH Lee Moffitt Cancer Center & Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesH Lee Moffitt Cancer Center & Research Institute
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A